Download - Advancing Type 2 Diabetes Care With Modern Insulins

Transcript
Page 1: Advancing Type 2 Diabetes Care With Modern Insulins

Advancing Type 2 Diabetes Care With Modern Insulins

Page 2: Advancing Type 2 Diabetes Care With Modern Insulins

Goals

Page 3: Advancing Type 2 Diabetes Care With Modern Insulins

Type 2 Diabetes Is Progressive

Page 4: Advancing Type 2 Diabetes Care With Modern Insulins

Most Patients Are Not Achieving HbA1C < 7%

Page 5: Advancing Type 2 Diabetes Care With Modern Insulins

DCCT Results: HbA1c and Relative Risk of Diabetic Complicationsa,b

Page 6: Advancing Type 2 Diabetes Care With Modern Insulins

By the Time of Diagnosis, β-Cell Decline Exceeds 50%

Page 7: Advancing Type 2 Diabetes Care With Modern Insulins

Most Patients With T2D Will Eventually Need Insulin

Page 8: Advancing Type 2 Diabetes Care With Modern Insulins

Basal Insulin Therapy in T2D

Page 9: Advancing Type 2 Diabetes Care With Modern Insulins

Basal Insulin Improves Glycemic Control

Page 10: Advancing Type 2 Diabetes Care With Modern Insulins

Basal Insulin Replacement Therapy

Page 11: Advancing Type 2 Diabetes Care With Modern Insulins

Currently Available Basal Insulins

Page 12: Advancing Type 2 Diabetes Care With Modern Insulins

Time-action Profiles Illustrate Variability

Page 13: Advancing Type 2 Diabetes Care With Modern Insulins

Limitations of Current Basal Insulins

Page 14: Advancing Type 2 Diabetes Care With Modern Insulins

How Often Does Hypoglycemia Occur?

Page 15: Advancing Type 2 Diabetes Care With Modern Insulins

When Does Hypoglycemia Occur?

Page 16: Advancing Type 2 Diabetes Care With Modern Insulins
Page 17: Advancing Type 2 Diabetes Care With Modern Insulins

Hypoglycemia Is Associated With ECG Abnormalities

Page 18: Advancing Type 2 Diabetes Care With Modern Insulins

Cost of Hypoglycemia

Page 19: Advancing Type 2 Diabetes Care With Modern Insulins

Insulin Analogs Are Associated With Lower Rates of

Hypoglycemia

Page 20: Advancing Type 2 Diabetes Care With Modern Insulins

In Search of Improved Pharmacokinetic/Pharmacodyna

mic Profiles

Page 21: Advancing Type 2 Diabetes Care With Modern Insulins

Why We Need Better Basal Insulins

Page 22: Advancing Type 2 Diabetes Care With Modern Insulins

Novel Basal Insulins on the Horizon

Page 23: Advancing Type 2 Diabetes Care With Modern Insulins

Desired Properties for A Basal Insulin Product Relative to Existing

Therapy

Page 24: Advancing Type 2 Diabetes Care With Modern Insulins
Page 25: Advancing Type 2 Diabetes Care With Modern Insulins
Page 26: Advancing Type 2 Diabetes Care With Modern Insulins

Similar Outcomes With Flexible and Fixed Once-Daily Degludec*

Dosing

Page 27: Advancing Type 2 Diabetes Care With Modern Insulins
Page 28: Advancing Type 2 Diabetes Care With Modern Insulins

Pegylated Lispro* vs Glargine in Adults With T2D at 12 Weeks

Page 29: Advancing Type 2 Diabetes Care With Modern Insulins
Page 30: Advancing Type 2 Diabetes Care With Modern Insulins

Investigational New Insulin Glargine U300 (300 U/mL, Gla-

300)

Page 31: Advancing Type 2 Diabetes Care With Modern Insulins

Glargine U300

Page 32: Advancing Type 2 Diabetes Care With Modern Insulins

Benefits of Newer Basal Insulins

Page 33: Advancing Type 2 Diabetes Care With Modern Insulins

Take-home Messages

Page 34: Advancing Type 2 Diabetes Care With Modern Insulins

Abbreviations

Page 35: Advancing Type 2 Diabetes Care With Modern Insulins

Abbreviations (cont)

Page 36: Advancing Type 2 Diabetes Care With Modern Insulins

References

Page 37: Advancing Type 2 Diabetes Care With Modern Insulins

References (cont)

Page 38: Advancing Type 2 Diabetes Care With Modern Insulins

References (cont)

Page 39: Advancing Type 2 Diabetes Care With Modern Insulins

References (cont)

Page 40: Advancing Type 2 Diabetes Care With Modern Insulins

References (cont)

Page 41: Advancing Type 2 Diabetes Care With Modern Insulins

References (cont)

Page 42: Advancing Type 2 Diabetes Care With Modern Insulins

References (cont)